AUS
NZ
UK
CA
USA
IND
_06_04_2026_05_16_02_212823.jpg)
Highlights
Amplia Therapeutics quotes additional fully paid ordinary securities on the ASX
The move is linked to a previously disclosed transaction to support company operations
Amplia focuses on drug development for cancer and fibrotic diseases
Amplia Therapeutics Limited (ASX:ATX), a biotechnology company listed on the All Ordinaries index, has announced the quotation of a significant number of new fully paid ordinary securities on the Australian Securities Exchange. This development, effective from the start of September, forms part of a broader transaction previously communicated by the company.
The quotation of these securities is expected to enhance the company's financial capacity while supporting its drug development initiatives focused on cancer and fibrotic diseases. The additional listing may increase the visibility of the company on the ASX and potentially broaden market engagement.
What does Amplia Therapeutics do?
Amplia Therapeutics Limited operates in the biotechnology sector, with a specialised focus on developing therapeutic treatments for oncology and fibrosis-related conditions. The company's strategy includes advancing a pipeline of drug candidates aimed at areas of significant unmet clinical need.
The company’s portfolio centres on the modulation of the focal adhesion kinase (FAK) pathway, which is believed to play a role in both tumor progression and fibrotic tissue development. Its lead candidates are intended for use in combination with existing therapies or as standalone treatments in advanced disease settings.
Who is leading the efforts behind Amplia’s growth?
Amplia Therapeutics is driven by a leadership team with expertise across scientific research, drug development, and corporate management. The team has focused on moving promising therapies from preclinical stages through to clinical trials, supported by partnerships and scientific advisory input.
In recent years, the company has also expanded its engagement with the regulatory framework and research institutions to further validate its core programs. These efforts align with its vision of creating differentiated therapies for complex diseases.
Why was the quotation of new securities important?
The addition of new securities to the ASX under the ticker ASX:ATX is part of a previously announced plan that could improve liquidity and help the company maintain momentum in its scientific programs. It also underscores the company's intent to remain active in the market while advancing its research efforts.
By boosting its market presence, Amplia may improve its access to strategic partners, collaborators, or future capital sources. This quotation follows a consistent theme of incremental development aimed at strengthening its positioning in the Australian biotech landscape.
What’s next for Amplia Therapeutics?
As Amplia Therapeutics continues to push forward with its clinical pipeline, the company is expected to maintain its focus on drug candidates that address aggressive cancers and chronic fibrotic diseases. Updates regarding its research progress, trial outcomes, or collaborations will likely shape the next phase of its corporate and scientific trajectory.
The current expansion of its securities on the ASX represents a step toward supporting these broader objectives within the biotechnology ecosystem.
